



## DHRS9 Is a Stable Marker of Human Regulatory Macrophages

Paloma Riquelme, Giada Amodio, Camila Macedo, Aurélie Moreau, Nataša Obermajer, Christoph Brochhausen, Norbert Ahrens, Tuija Kekarainen, Fred Fändrich, Cristina Cuturi, et al.

### ► To cite this version:

Paloma Riquelme, Giada Amodio, Camila Macedo, Aurélie Moreau, Nataša Obermajer, et al.. DHRS9 Is a Stable Marker of Human Regulatory Macrophages. *Transplantation*, 2017, 101 (11), pp.2731-2738. 10.1097/TP.0000000000001814 . inserm-02154878

**HAL Id: inserm-02154878**

**<https://inserm.hal.science/inserm-02154878>**

Submitted on 13 Jun 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## OPEN

# DHRS9 Is a Stable Marker of Human Regulatory Macrophages

Paloma Riquelme, PhD,<sup>1</sup> Giada Amodio, PhD,<sup>2</sup> Camila Macedo, MD,<sup>3</sup> Aurelie Moreau, PhD,<sup>4,5,6</sup> Nataša Obermajer, PhD,<sup>7</sup> Christoph Brochhausen, MD,<sup>8</sup> Norbert Ahrens, MD,<sup>9</sup> Tuija Kekarainen, PhD,<sup>10,11</sup> Fred Fändrich, MD, PhD,<sup>12</sup> Cristina Cuturi, MD,<sup>4,5,6</sup> Silvia Gregori, PhD,<sup>2</sup> Diana Metes, MD,<sup>3</sup> Hans J. Schlitt, MD,<sup>1</sup> Angus W. Thomson, PhD, DSc,<sup>3</sup> Edward K. Geissler, PhD,<sup>1</sup> and James A. Hutchinson, MD, PhD<sup>1</sup>

**Background.** The human regulatory macrophage (Mreg) has emerged as a promising cell type for use as a cell-based adjunct immunosuppressive therapy in solid organ transplant recipients. In this brief report, dehydrogenase/reductase 9 (DHRS9) is identified as a robust marker of human Mregs. **Methods.** The cognate antigen of a mouse monoclonal antibody raised against human Mregs was identified as DHRS9 by immunoprecipitation and MALDI-MS sequencing. Expression of DHRS9 within a panel of monocyte-derived macrophages was investigated by quantitative PCR, immunoblotting and flow cytometry. **Results.** DHRS9 expression discriminated human Mregs from a panel of in vitro derived macrophages in other polarisation states. Likewise, DHRS9 expression distinguished Mregs from a variety of human monocyte-derived tolerogenic antigen-presenting cells in current development as cell-based immunotherapies, including Tol-DC, Rapa-DC, DC-10, and PGE<sub>2</sub>-induced myeloid-derived suppressor cells. A subpopulation of DHRS9-expressing human splenic macrophages was identified by immunohistochemistry. Expression of DHRS9 was acquired gradually during in vitro development of human Mregs from CD14<sup>+</sup> monocytes and was further enhanced by IFN- $\gamma$  treatment on day 6 of culture. Stimulating Mregs with 100 ng/mL lipopolysaccharide for 24 hours did not extinguish DHRS9 expression. Dhhrs9 was not an informative marker of mouse Mregs. **Conclusion.** DHRS9 is a specific and stable marker of human Mregs.

(*Transplantation* 2017;101: 2731–2738)

Several immunoregulatory cell-based products are presently being investigated as adjunct immunosuppressive agents in early-phase clinical trials in solid organ transplantation.<sup>1</sup> One

particularly promising candidate cell type is the regulatory macrophage (Mreg). The human Mreg represents a unique state of macrophage polarisation, which is distinguished

Received 5 December 2016. Revision received 2 May 2017.

Accepted 4 May 2017.

<sup>1</sup> Department of Surgery, University Hospital Regensburg, Regensburg, Germany.

<sup>2</sup> San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Division of Regenerative Medicine, Stem Cells and Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.

<sup>3</sup> Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA.

<sup>4</sup> INSERM UMR1064, Center for Research in Transplantation and Immunology, Nantes, France.

<sup>5</sup> CHU de Nantes, Institut de Transplantation Urologie Néphrologie (ITUN), Nantes, France.

<sup>6</sup> Université de Nantes, Nantes, France.

<sup>7</sup> Division of Surgical Oncology, University of Pittsburgh, Hillman Cancer Center, Pittsburgh, PA.

<sup>8</sup> Institute of Pathology, University Hospital Regensburg, Regensburg, Germany.

<sup>9</sup> Department of Transfusion Medicine, University Hospital Regensburg, Regensburg, Germany.

<sup>10</sup> Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.

<sup>11</sup> FinVector Vision Therapies Oy, Mikrokatu 1S, Kuopio, Finland.

<sup>12</sup> Institute for Applied Cell Therapy, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany.

P.R. is supported by the Deutsche Forschungsgemeinschaft through award RI 2587/1-1. The authors gratefully acknowledge financial support from the EU-funded Reprogramming the Immune System for Establishment of Tolerance (RiSET) network, the EU-funded ONE Study Consortium and the Regensburg Center for Interventional Immunology. The authors thank Miltenyi Biotec for lending a CliniMACS device to The ONE Study Workshop.

J.A.H. and E.K.G. are the named inventors on European Patent Office (EPO) filing 16159985.6-1402 dated 11.03.2016, "Immunoregulatory cells and methods for their production." All other authors declare no conflict-of-interest.

P.R. and J.A.H. designed and conducted experiments, analyzed data and prepared manuscript. G.A., C.M., A.M., N.O., and C.B. conducted and/or analyzed experiments. N.A., C.C., S.G., A.W.T., and E.K.G. provided critical feedback. T.K., F.F., D.M., H.J.S., and all other authors approved the final article.

Correspondence: Paloma Riquelme, PhD, Department of Surgery, University Hospital Regensburg Franz-Josef-Strauss-Allee 11 93053 Regensburg, Germany. (paloma.riquelme@klinik.uni-regensburg.de).

Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

ISSN: 0041-1337/17/10111-2731

DOI: 10.1097/TP.0000000000001814

**TABLE 1.**  
**Summary of the methods used to generate different monocyte derived cells**

	Medium	Stimulation (last 18 h)	Culture, d	Reference
Mreg	RPMI 1640, 10% HABS, 5 ng/mL M-CSF.	25 ng/mL	7	(2)
Mreg wo IFNγ	RPMI 1640, 10% HABS, 5 ng/mL M-CSF.	none	7	(2)
Resting Mφ	RPMI 1640, 20% FCS, 100 ng/mL M-CSF. On day 6, 5% FCS.	none	7	(2) (6)
LPS + IFN-γ Mφ	RPMI 1640, 20% FCS, 100 ng/mL M-CSF. On day 6, 5% FCS.	20 ng/mL rhIFN-γ +100 ng/mL LPS	7	(2) (6)
IFN-γ-Mφ	RPMI 1640, 10% FCS, 100 ng/mL M-CSF.	20 ng/mL rhIFNγ	7	(2) (7)
IL-4 Mφ	RPMI 1640, 20% FCS, 100 ng/mL M-CSF. On day 6, 5% FCS.	20 ng/mL rhIL-4	7	(2) (6)
GC Mφ	RPMI 1640, 20% FCS, 100 ng/mL M-CSF. On day 6, 5% FCS.	10 <sup>-7</sup> M dexamethasone	7	(2) (9)
Ig Mφ	IVlg coated wells. RPMI 1640, 10% FCS, 100 ng/mL M-CSF. On day 6, 5% FCS.	100 ng/mL LPS	7	(2)
iDC	IMDM, 10% FBS, 1000 U/mL rhGM-CSF, 1000 U/mL rhIL-4.	none	6	(21)
Tol-DC	AIM-V, 100 U/mL rhGM-CSF	none	6	(15)
Rapa-DC	AIM-V, 1000 U/mL rhGM-CSF, 1000 U/mL rhIL-4, from d2 10 ng/mL Rapamycin.	none	7	(16,17)
DC-10	RPMI 1640, 10% FBS, 100 ng/mL rhGM-CSF, 10 ng/mL rhIL-4, 10 ng/mL rhIL-10.	none	7	(18-20)
MDSC	IMDM, 10% FBS, 1000 U/mL rhGM-CSF, 1000 U/mL rhIL-4, 10 <sup>-6</sup> M PGE <sub>2</sub> .	none	6	(21,22)

FCS, fetal calf serum; HABS, human AB serum; MDSC, myeloid-derived suppressor cell.

from other activation states by a constellation of cell-surface markers and potent T cell suppressor function.<sup>2</sup> Human Mregs suppress mitogen-stimulated T cell proliferation in vitro through interferon-gamma (IFN-γ)-induced indoleamine 2,3-dioxygenase (IDO) activity, as well as contact-dependent deletion of activated T cells.<sup>3</sup> In addition, Mregs drive the development of activated induced regulatory T cells that, in turn, suppress the proliferation and activity of effector T cells (Riquelme-P et al, unpublished). Human Mregs derive from CD14<sup>+</sup> peripheral blood monocytes when cultured in the presence of macrophage colony-stimulating factor (M-CSF) and high concentrations of heat-inactivated human serum for more than 4 days before stimulation with IFN-γ. A proprietary good manufacturing practice (GMP)-compliant process for manufacturing a therapeutic product, known as Mreg\_UKR, containing human Mregs has been established at a commercial pharmaceutical manufacturing facility in Germany.<sup>4</sup> Now, Mreg\_UKR is being investigated in a Phase-I/II trial as a means of promoting immune regulation in kidney transplant recipients with the

objective of safely minimizing maintenance immunosuppression (clinicaltrials.gov: NCT02085629).

With the objective of discovering novel markers of human Mregs, mouse monoclonal antibodies (mAb) were raised against human Mregs. In this brief report, we identify dehydrogenase/reductase 9 (DHRS9) as the antigen recognized by one such Mreg-reactive mAb (ASOT1). Within a panel of differently polarised monocyte-derived macrophages, expression of DHRS9 mRNA and protein was essentially restricted to Mregs. Lipopolysaccharide (LPS) stimulation did not extinguish DHRS9 expression by Mregs; therefore, DHRS9 behaves as a relatively specific and stable marker of in vitro generated human Mregs.

MATERIALS AND METHODS

Generation of Human Monocyte-Derived Macrophages

Mregs and IFN-γ-Mφ were generated according to previously described methods<sup>2</sup> from peripheral blood leucocytes

**TABLE 2.**  
**Antibodies used for flow cytometry**

Antigen	CD14	Isotype	CD16	Isotype	CD163	Isotype	CD282	Isotype
Clone	MφP9	27-35	3G8	679.1Mc7	GHI/61	MOPC-21	TL2.1	eBM2a
Isotype	mlgG2b	mlgG2b	mlgG1	mlgG1	mlgG1	mlgG1	mlgG2a	mlgG2a
Conjugate	APC	APC	APC	APC	PE	PE	FITC	FITC
Test vol., μL	5.00	40.00	10.00	10.00	20.00	20.00	5.00	5.00
Supplier	BD	BD	BC	BC	BD	BD	eBio	eBio
Cat. no.	345787	555745	B00845	IM2475U	556018	555749	11-9922	11-4724
Status	CE/VD	RUO	ASR	RUO	RUO	RUO	RUO	RUO

**TABLE 3.**  
**Primer sequences and cycling conditions**

Gene	Primer sequences (5'-3')	Annealing temperature, °C	Amplicon length, bp
DHRS9	TGACCGACCCAGAGAATGTCAA GCCGGGAACACCAAGCATTATT	60	101
GAPDH	TTGCCATCAATGACCCCTTCA CGCCCCACTTGATTTTGA	57	173

obtained as a by-product of thrombocyte collection from healthy donors. Briefly, CD14<sup>+</sup> monocytes were isolated from Ficoll-prepared peripheral blood mononuclear cells (PBMC) by positive-selection with anti-CD14 microbeads (Miltenyi, Bergisch-Gladbach) and were then plated in 6-well Cell+ plates (Sarstedt, Nümbrecht) at 10<sup>5</sup> cells/cm<sup>2</sup> in RPMI-1640 (Lonza, Cologne) supplemented with 10% heat-inactivated human AB serum (Lonza), 2 mM Glutamax (Invitrogen, Karlsruhe), 100 U/mL penicillin (Lonza), 100 µg/mL streptomycin (Lonza), and rhM-CSF (R&D Systems, Wiesbaden-Nordenstadt) at 5 ng/mL carried on 0.1% human albumin (CSL-Behring, Hattersheim-am-Main). On day 6 of culture, cells were stimulated for a further 18 to 24 hours with 25 ng/mL rhIFN-γ (Chemicon, Billerica, MA). IFN-γ-stimulated macrophages (IFN-γ-Mφ) were generated by cultivating CD14<sup>+</sup> monocytes under identical conditions to Mregs except that human serum was replaced with 10% heat-inactivated fetal calf serum (Biochrom, Berlin). Macrophages (Mφ) in other defined states of polarization<sup>5</sup> were generated from positively isolated CD14<sup>+</sup> monocytes according to protocols adapted from the literature<sup>6-9</sup> and previously published methods<sup>2</sup> (see Table 1 for a summary of culture

conditions). The tolerogenic monocyte-derived therapeutic cell products<sup>10</sup> shown in Figures 2F and G were prepared during The ONE Study workshop from CD14<sup>+</sup> monocytes isolated by CliniMACS from leucapheresis products from 6 healthy, male donors (Table 1).

Flow Cytometry

Cells were stained for flow cytometry following standardized protocols, in brief, surface staining was performed at 4° C in staining buffer (DPBS/1% BSA/0.02% NaN<sub>3</sub>/10% FcR-block, Miltenyi) for 60 minutes using the directly-conjugated antibodies listed in Table 2. In all cases, saturating antibody concentrations were used and dead cells were excluded by 7-AAD staining (BD Biosciences). Data were captured with a Calibur cytometer (BD Biosciences) and analyzed with FlowJo (Tree Star Inc).

Western Blotting, Immunoprecipitation, and Protein Sequencing


Gel electrophoresis and immunoblotting were performed per conventional methods. Protein A/G sepharose (Sigma-Aldrich) was used to immunoprecipitate the antigen of ASOT1, which was then sequenced by MALDI-MS (Proteome Factory, Berlin).

Immunocytochemistry and Histology

Cytological specimens were stained as previously described elsewhere.<sup>11</sup> Tissue sections were stained with anti-DHRS9 mAb (clone 3C6) following established protocols and were then evaluated by a qualified clinical histopathologist.

PCR

RNA was isolated using RNeasy Plus kits (Qiagen). SuperScript-III (Invitrogen) was used for reverse-transcription reactions.




**FIGURE 1.** Comparative phenotyping of Mregs and other human macrophages. Low or absent expression of CD14, CD16, TLR2 and CD163 discriminated human Mregs from a panel of differently stimulated human monocyte-derived macrophages, including resting Mφ, LPS + IFNγ-stimulated Mφ, IL-4-stimulated Mφ, immunoglobulin (Ig)-stimulated Mφ and GC-stimulated Mφ. Values represent mean ± SD of n = 6 donors.

qPCR was performed with a LightCycler real-time PCR system using the FastStart DNA Master SYBR Green I kit (Roche Diagnostics). DHRS9 primer sequences and cycling conditions are presented in Table 3. DHRS9 signals were normalised against *GAPDH* mRNA expression. ALDH1A1, ALDH1A2, BCO1, BCO2, and CD1C were amplified using predesigned primer pairs (QuantiTect, Qiagen) per the manufacturer's recommendations. PCR specificity was confirmed sequencing of amplicons (MWG Biotech).

**RESULTS**

**DHRS9 Expression Uniquely Identifies Mregs Amongst Comparator Macrophages**

Although the CD14<sup>−/low</sup> CD16<sup>−/low</sup> TLR2<sup>−</sup> and CD163<sup>−/low</sup> cell-surface phenotype distinguished human Mregs from a variety of differently polarised monocyte-derived macrophages, this specification relies upon the absence of marker expression in Mregs (Figure 1). To identify positive markers of Mregs, a



**FIGURE 2.** DHRS9 expression distinguishes human Mregs from monocyte-derived macrophages and DCs. A, In immunocytochemistry, the ASOT1 mAb recognized an antigen expressed by Mregs, but not comparator macrophages. B, An antigen of ~35 kDa was specifically immunoprecipitated by ASOT1 and was subsequently identified by MALDI-MS as DHRS9. C, Strong *DHRS9* mRNA expression was detected in Mregs, but not comparator macrophage types ( $n = 6$ ; mean  $\pm$  SD). D, ASOT1 precipitated an antigen which was also recognized by an anti-DHRS9 rabbit pAb (generated in-house) and a mouse mAb (clone 3C6, Abnova), confirming that ASOT1 recognizes DHRS9. E, Immunoblotting with our custom-made rabbit anti-DHRS9 pAb demonstrated that DHRS9 protein expression distinguishes Mregs from comparator macrophages. F, *DHRS9* mRNA expression distinguished human Mregs from a panel of tolerogenic monocyte-derived therapeutic cell products. G, DHRS9 protein was detected in human Mregs but not other tolerogenic monocyte-derived therapeutic cell products using a commercial rabbit anti-DHRS9 pAb (ab98155, Abcam).




series of mAb were generated by vaccinating mice with human Mreg lysates. Screening these mAb by immunocytochemistry identified a mAb clone (ASOT1) that reacted strongly with Mregs, but not other monocyte-derived macrophages (M $\phi$ ), including resting M $\phi$ , LPS + IFN $\gamma$ -stimulated M $\phi$  and IL-4-stimulated M $\phi$  (Figure 2A). By immunoprecipitation and MALDI-MS sequencing of its antigen, ASOT1 was shown to recognize DHRS9, a little-studied retinol dehydrogenase of the short-chain dehydrogenase/reductase (SDR) family of NAD(P)(H)-dependent oxidoreductases<sup>12-14</sup> (Figure 2B). Quantitative PCR confirmed that high-level expression of *DHRS9* mRNA expression was restricted to Mregs within the panel of comparator macrophages (Figure 2C). A rabbit polyclonal antibody (pAb) generated in-house against a synthetic peptide (CTDPENVKRTAQWVKVQVGEKG) corresponding to an N-terminal epitope of DHRS9 reacted against a protein of ~35 kDa immunoprecipitated by ASOT1 (Figure 2D). Since a commercially-available mAb (clone 3C6, Abnova) against DHRS9 also reacted with the same immunoprecipitated protein, it was concluded that both ASOT1 and our custom-made rabbit pAb recognized DHRS9. Using our custom-made rabbit pAb for immunoblotting, DHRS9 protein expression was shown to be unique to Mregs within a panel of comparator human macrophages (Figure 2E). DHRS9 expression was not diminished after stimulation of Mregs with 100 ng/mL LPS for 24 hours (Figures 2C and E). To ascertain whether DHRS9 expression is a unique property of Mregs or a common characteristic of tolerogenic monocyte-derived cells, DHRS9 gene and protein expression was examined in samples obtained from *The ONE Study* Workshop on 'Tolerogenic Monocyte-derived Antigen Presenting Cells.' *DHRS9* mRNA expression was significantly higher


in Mregs than immature monocyte-derived dendritic cells (mo-DC), tolerogenic DC (Tol-DC),<sup>15</sup> Rapamycin-treated DC (Rapa-DC),<sup>16,17</sup> IL-10 conditioned DC (DC-10)<sup>18-20</sup> or PGE<sub>2</sub>-induced myeloid-derived suppressor cell<sup>21,22</sup> (Figure 2F). Likewise, at the protein level, DHRS9 expression was greater in Mregs than any of these comparator monocyte-derived cells (Figure 2G).

### Factors Affecting DHRS9 Expression in Human Macrophages

DHRS9 expression increased steadily throughout the transition of monocytes to Mregs in culture and was further upregulated by IFN- $\gamma$  stimulation on day 6 (Figure 3A). Treatment of resting macrophages with IL-4, plate-bound Ig, dexamethasone, IFN- $\gamma$  or LPS + IFN- $\gamma$  did not induce DHRS9 expression to the same level as Mregs (Figure 2C&E). Reanalyzing publicly available microarray data<sup>23</sup> revealed an induction of *DHRS9* in glucocorticoid (GC)-stimulated M $\phi$  and IFN- $\gamma$ -stimulated M $\phi$ , but no significant upregulation under 26 other treatment conditions, which are meant to encompass all known states of human monocyte-derived macrophage polarisation (Figure 3B). By contrast, 14 treatment conditions led to more than twofold downregulation of *DHRS9* expression. Notably, GC- and IFN- $\gamma$ -induced *DHRS9* mRNA expression was weak compared with DHRS9 expression in Mregs at the mRNA (Figure 2C) and protein level (Figure 2E). To characterise DHRS9 expression by Mregs at the single-cell level, a flow cytometry method was developed for detecting DHRS9 expression using mAb 3C6 (Figure 3C). DHRS9 signal was continuously distributed in Mreg populations, indicating that expression was not restricted to a subset of cells within Mreg cultures (Figure 3D).



**FIGURE 3.** Factors affecting DHRS9 expression in human macrophages. A, DHRS9 mRNA expression increased steadily over 7 days of culture as human monocytes transitioned to Mregs and was further induced by IFN- $\gamma$  stimulation on day 6 ( $n = 6$ ; mean  $\pm$  SD). B, Pattern of DHRS9 expression in a publicly available microarray data set encompassing 29 differently stimulated human monocyte-derived macrophages (Xue, J. et al, *Immunity*; GEO accession: GSE47189). More than twofold upregulation of DHRS9 was elicited by treatment with either 1  $\mu$ M dexamethasone or 200 IU/mL IFN- $\gamma$ . HDL, high-density lipoprotein; IC, immune complex; P3C, Pam3CSK4; PGE<sub>2</sub>, Prostaglandin E<sub>2</sub>; LA, lauric acid; OA, oleic acid; LiA, linoleic acid; SA, steric acid; PA, palmitic acid; TPP, TNF + PGE<sub>2</sub> + P3C. C, Optimization of an intracellular staining method for detection of DHRS9 expression in human macrophages using PE-conjugated anti-DHRS9 mAb clone 3C6. D, Quantification of DHRS9 expression in human Mregs, IFN- $\gamma$  M $\phi$  and resting M $\phi$  by flow cytometry.



**FIGURE 4.** Human Mregs express enzymes involved in retinoid metabolism. A, A schematic overview of retinoid metabolism. DHRS9 is a member of the SDR family of NAD(P)(H)-dependent oxidoreductases that catalyze interconversion of retinol and retinal. B, Mregs expressed *ALDH1A1*, *ALDH1A2* and *BCO2* mRNA, as well as the RA-responsive gene, *CD1D* (n = 3).

DHRS9 expression was greater in Mregs than in either resting M $\phi$  or IFN $\gamma$ -stimulated M $\phi$ . Consistent with results from qPCR and microarray analyses, a very low-level of DHRS9 expression was observed in IFN $\gamma$ -stimulated M $\phi$ .

#### Human Mregs Express Enzymes Involved in Retinoid Metabolism

The SDR family of retinol dehydrogenases is responsible for conversion of retinol to retinal, which is further metabolized to retinoic acid (RA) by retinal dehydrogenases<sup>14,24</sup> (Figure 4A): expression of *ALDH1A1* and *ALDH1A2* mRNA was detectable in Mregs (Figure 4B). Retinol is liberated from  $\beta$ -carotene through the action of beta-carotene monooxygenases: expression of *BCO2*, but not *BCO1*, was also detected in Mregs (Figure 4B). Accordingly, in principle, Mregs express the necessary apparatus to convert retinol and  $\beta$ -carotene to RA. *CD1D* mRNA expression, which is upregulated by RA through RAR $\alpha$  activation<sup>25</sup> was also detected in Mregs.

#### DHRS9<sup>+</sup> Macrophages Are Naturally Present in Human Spleen

Methods for producing human Mregs as a cell-based therapy have been optimized for generating a phenotypically homogeneous and stable population of cells. By contrast, macrophage subsets isolated from tissues tend to be much more heterogeneous. For this reason, in vitro derived human Mregs must be regarded as an artificial cell population; nevertheless, it may be interesting and informative to


ask what naturally occurring macrophage subsets are most like in vitro derived Mregs. To ascertain whether DHRS9-expressing macrophages normally exist in tissues, an immunohistochemical staining procedure for fixed specimens was established using mAb 3C6. Soref and colleagues previously reported DHRS9 expression by stratified squamous epithelium of human skin, which was confirmed using our staining method and reagents (data not shown). In earlier work, our group tracked ex vivo generated, radio-labelled allogeneic human Mregs after intravenous administration to a prospective kidney transplant recipient. These studies showed Mregs trafficked in blood through the lung to accumulate in spleen, liver, and bone marrow.<sup>3</sup> Therefore, human spleen sections were stained for DHRS9, revealing a minor population of DHRS9-expressing cells with typical macrophage morphology that appeared to be most prevalent in the subcapsular red pulp (Figure 5). Although it is not possible to conclude that these splenic red pulp macrophages are a physiological counterpart of the in vitro derived human Mreg, the existence of a naturally-occurring DHRS9<sup>+</sup> macrophage population suggests that DHRS9 expression by ex vivo generated Mregs is not purely an artefact of cell culture.

#### Dhrs9 Expression Is Not Upregulated in Mouse Mregs


To ascertain whether *Dhrs9* expression could also be used as a marker of mouse Mregs, a previously published microarray data set was reinterrogated.<sup>26</sup> This data set comprised triplicate whole-genome gene-expression profiles from CD11b<sup>+</sup> Ly6C<sup>+</sup> Ly6G<sup>−</sup> bone marrow monocytes, monocyte-derived Mregs, monocyte-derived DC, and 8 other differently treated macrophage populations from C57BL/6 mice (Figure 6). *Dhrs9* expression was not upregulated in Mregs or in any other comparator population. Moreover, no other SDR-family member was selectively upregulated in Mregs, nor any comparator macrophage type. Accordingly, *Dhrs9* expression is not useful for distinguishing mouse Mregs from other monocyte-derived cell types.<sup>27</sup>

#### DISCUSSION

Here, we identify DHRS9 expression as a relatively specific and stable marker of in vitro generated human Mregs, which could be detected by qPCR, immunoblotting, immunohistochemistry and flow cytometry. Within the panel of comparator monocyte-derived macrophages used for this



**FIGURE 5.** Identification of DHRS9<sup>+</sup> M $\phi$  in the subcapsular red pulp of human spleen. Immunohistochemical staining of 3  $\mu$ m, H&E-counterstained sections of fixed, paraffin-embedded human spleen revealed a population of DHRS9<sup>+</sup> macrophages. A, DHRS9<sup>+</sup> M $\phi$  detected with mAb 3C6 appeared to be most prevalent in the subcapsular red pulp. Original magnification, 20 $\times$ . B, Negative control. Original magnification, 20 $\times$ . C, A high density of DHRS9<sup>+</sup> macrophages were detected in the subcapsular splenic red pulp using mAb 3C6. Original magnification, 40 $\times$ . D, DHRS9 staining with mAb 3C6 was restricted to cytoplasm of cells with typical macrophage morphology. Original magnification, 40 $\times$ .



**FIGURE 6.** DHRS9 is not a marker of mouse Mregs. Microarray analysis of SDR-family gene expression in monocyte-derived macrophages and DCs from C57BL/6 mice (Riquelme, P. et al, Molecular Therapy; GEO accession: GSE32690). No differential expression of DHRS9 or other SDR family members was observed between mouse Mregs and comparator cell types.

study, DHRS9 expression was principally restricted to Mregs. DHRS9 expression remained stable after LPS stimulation, which shows that certain aspects of the Mreg phenotype are refractory to repolarising signals. Hence, DHRS9 expression appears to be a unique and relatively stable characteristic of human Mregs as a “cell type.”<sup>28,29</sup>

As yet, the conditions leading to DHRS9 expression in human Mregs are not fully defined, but GC and IFN- $\gamma$  appear to enhance DHRS9 expression to some degree. We hypothesize that presently undefined components of serum influence the *in vitro* development of Mregs from monocytes. In future experiments, assaying DHRS9 expression should facilitate screening of serum-derived factors for Mreg-inducing or -suppressing activity. The functional implications of DHRS9 expression by human Mreg are not clear. Although Mregs express the necessary retinoid metabolising enzymes, we cannot directly infer that Mregs generate RA. Nevertheless, it is well-known that certain tissue-resident macrophage populations responsible for maintaining tissue homeostasis and preventing constitutive inflammation, such as those in the gut, suppress T cell reactions and induce regulatory T cells through production of RA.<sup>30</sup> We speculate that *ex vivo* generated human Mregs may act through similar pathways when administered to patients.

In conclusion, DHRS9 is a relatively stable and specific marker of human Mreg. The ability to positively identify DHRS9-expressing macrophages as Mregs should greatly facilitate future *in vitro* studies with these cells and may be useful in searching for a naturally occurring counterpart.

## ACKNOWLEDGMENTS

**Attribution:** This article makes use of a gene expression profiling data set published by Jia Xue et al, in *Immunity*, 2014; 40:274-288 under a CC-BY-3.0 Open Access License. The original article and data can be accessed at <http://dx.doi.org/10.1016/j.immuni.2014.01.006>. **Personal acknowledgments:** The authors are indebted to Dr. Anna Sotnikova (Department of Surgery, UKSH) for her kind gift of the ASOT1 mAb.

## REFERENCES

- Hutchinson JA, Geissler EK. Now or never? The case for cell-based immunosuppression in kidney transplantation. *Kidney Int.* 2015;87:1116–1124.
- Hutchinson JA, Riquelme P, Geissler EK, et al. Human regulatory macrophages. *Methods Mol Biol.* 2011;677:181–192.
- Hutchinson JA, Riquelme P, Sawitzki B, et al. Cutting edge: immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. *J Immunol.* 2011;187:2072–2078.
- Ahrens N, Riquelme P, Bach C, et al. Donor-specific anti-HLA antibodies present in pooled human serum do not prevent development of human Mreg\_UKR from monocytes in culture. *Transplantation.* 2017;101:e188–e190.
- Hutchinson JA. Macrophages in transplantation. *Transplantation.* 2015;99:898–899.
- Martinez FO, Gordon S, Locati M, et al. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. *J Immunol.* 2006;177:7303–7311.
- Munn DH, Shafizadeh E, Attwood JT, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. *J Exp Med.* 1999;189:1363–1372.
- Sironi M, Martinez FO, D'Ambrosio D, et al. Differential regulation of chemokine production by Fc $\gamma$  receptor engagement in human monocytes: association of CCL1 with a distinct form of M2 monocyte activation (M2b, Type 2). *J Leukoc Biol.* 2006;80:342–349.
- Kzyshkowska J, Workman G, Cardo-Vila M, et al. Novel function of alternatively activated macrophages: stabilin-1-mediated clearance of SPARC. *J Immunol.* 2006;176:5825–5832.
- Rosborough BR, Raich-Regué D, Turnquist HR, et al. Regulatory myeloid cells in transplantation. *Transplantation.* 2014;97:367–379.
- Hutchinson JA, Riquelme P, Wundt J, et al. Could treatment with neohepatocytes benefit patients with decompensated chronic liver disease? *Am J Hematol.* 2007;82:947–948.
- Soref CM, Di YP, Hayden L, et al. Characterization of a novel airway epithelial cell-specific short chain alcohol dehydrogenase/reductase gene whose expression is up-regulated by retinoids and is involved in the metabolism of retinol. *J Biol Chem.* 2001;276:24194–24202.
- Jones RJ, Dickerson S, Bhende PM, et al. Epstein-Barr virus lytic infection induces retinoic acid-responsive genes through induction of a retinol-metabolizing enzyme, DHRS9. *J Biol Chem.* 2007;282:8317–8324.
- Lidén M, Eriksson U. Understanding retinol metabolism: structure and function of retinol dehydrogenases. *J Biol Chem.* 2006;281:13001–13004.
- Moreau A, Valey E, Bouchet-Delbos L, et al. Cell therapy using tolerogenic dendritic cells in transplantation. *Transplant Res.* 2012;1:13.
- Macedo C, Turnquist HR, Castillo-Rama M, et al. Rapamycin augments human DC IL-12p70 and IL-27 secretion to promote allogeneic Type 1 polarization modulated by NK cells. *Am J Transplant.* 2013;13:2322–2333.
- Macedo C, Turquist H, Metes D, et al. Immunoregulatory properties of rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation. *Transplant Res.* 2012;1:16.
- Amodio G, Comi M, Tomasoni D, et al. HLA-G expression levels influence the tolerogenic activity of human DC-10. *Haematologica.* 2015;100:548–557.
- Amodio G, Gregori S. Human tolerogenic DC-10: perspectives for clinical applications. *Transplant Res.* 2012;1:14.
- Gregori S, Tomasoni D, Pacciani V, et al. Differentiation of type 1T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. *Blood.* 2010;116:935–944.
- Obermajer N, Muthuswamy R, Lesnock J, et al. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. *Blood.* 2011;118:5498–5505.
- Obermajer N, Kalinski P. Generation of myeloid-derived suppressor cells using prostaglandin E2. *Transplant Res.* 2012;1:15.
- Xue J, Schmidt SV, Sander J, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. *Immunity.* 2014;40:274–288.
- Pares X, Farres J, Kedishvili N, et al. Medium- and short-chain dehydrogenase/reductase gene and protein families: Medium-chain and short-chain dehydrogenases/reductases in retinoid metabolism. *Cell Mol Life Sci.* 2008;65:3936–3949.



25. Szatmari I, Pap A, Ruhl R, et al. PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. *J Exp Med*. 2006;203:2351–2362.
26. Riquelme P, Tomiuk S, Kammler A, et al. IFN- $\gamma$ -induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. *Mol Ther*. 2013;21:409–422.
27. Carretero-Iglesia L, Bouchet-Delbos L, Louvet C, et al. Comparative study of the immunoregulatory capacity of in vitro generated tolerogenic dendritic cells, suppressor macrophages, and myeloid-derived suppressor cells. *Transplantation*. 2016;100:2079–2089.
28. Turnquist HR, Thomson AW. Identity crisis. *Transplantation*. 2016;100:258–259.
29. Riquelme P. Regulatory myeloid cells for tolerance-inducing therapy: finding their own identity. *Transplantation*. 2016;100:2022–2023.
30. Raverdeau M, Mills KH. Modulation of T cell and innate immune responses by retinoic acid. *J Immunol*. 2014;192:2953–2958.